Text Size
69 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3 (69 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown † Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Genetic: microarray analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
2 Recruiting Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: paclitaxel;   Drug: sorafenib tosylate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
3 Recruiting MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Procedure: therapeutic conventional surgery;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Procedure: neoadjuvant therapy
4 Recruiting Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Condition: Breast Cancer
Interventions: Drug: nab-paclitaxel;   Drug: trastuzumab;   Drug: Doxorubicin;   Drug: cyclophosphamide
5 Recruiting Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: tivantinib;   Other: laboratory biomarker analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method
6 Recruiting Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Condition: Breast Cancer
Interventions: Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: adjuvant therapy;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation
7 Recruiting A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel + LCL161;   Drug: paclitaxel
8 Recruiting DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Digoxin
9 Not yet recruiting Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
Condition: Breast Cancer
Intervention: Drug: Capecitabine
10 Recruiting Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Abraxane;   Drug: Bevacizumab;   Drug: Carboplatin
11 Recruiting Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Conditions: Breast Cancer;   Breast Cancer Stage II-III
Intervention: Drug: Docetaxel- Carboplatin
12 Unknown † PET-Guided Chemotherapy and Hormone Therapy in Treating Women With Previously Untreated Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Biological: trastuzumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: epirubicin hydrochloride;   Drug: vinorelbine tartrate;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Procedure: neoadjuvant therapy;   Procedure: positron emission tomography;   Procedure: therapeutic conventional surgery
13 Unknown † Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Simvastatin
14 Recruiting Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Drug: BKM120 + lapatinib
15 Recruiting Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Eribulin
16 Not yet recruiting The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: gefitinib
17 Recruiting A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Epirubicin+Cyclophosphamide;   Drug: liposomal-doxorubicin+Cyclophosphamide
18 Unknown † Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor
Condition: Breast Cancer
Intervention: Drug: Doxorubicin, Cyclophosphamide
19 Recruiting ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Conditions: Neoplasms, Breast;   Breast Cancer
Interventions: Drug: Lapatinib;   Biological: Trastuzumab
20 Recruiting Clinical Value of 89Zr-trastuzumab PET
Condition: Metastatic Breast Cancer
Intervention: Drug: 89Zr-trastuzumab injection
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years